SalvaRx Group plc

Equities

SALV

IM00BZ4SS228

Biotechnology & Medical Research

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		-47.06%	-.--%

2019	SalvaRx Evaluates Takeover Opportunities	CI
2019	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI

SalvaRx Seeks Acquisitions

June 28, 2018 at 09:30 am IST

SalvaRx Group plc (AIM:SALV) seeks acquisitions. The company continues to identify potential investments or acquisitions. The company expects to grow further by acquisition, investment or licensing arrangements as it identifies novel cancer immunotherapies.

Latest news about SalvaRx Group plc

SalvaRx Evaluates Takeover Opportunities	26/19/26	CI
Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	26/19/26	CI
Salvarx Group plc Reports Earnings Results for the Full Year Ended December 31, 2018	28/19/28	CI
Portage Biotech Inc. (OTCPK:PTGE.F) completed the acquisition of SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile.	08/19/08	CI
SalvaRx Group plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	27/18/27	CI
Portage Biotech Inc. (OTCPK:PTGE.F) (‘Portage’) entered into a conditional sale agreement to acquire SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile for $80.5 million.	14/18/14	CI
SalvaRx Group plc Announces Consolidated Earnings Results for the Year Ended December 31, 2017	28/18/28	CI
SalvaRx Seeks Acquisitions	28/18/28	CI
SalvaRx Announces an Unsecured $1 Million Loan	26/18/26	CI
SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017	27/17/27	CI
SalvaRx Group plc Announces Final Audited Consolidated Earnings Results for the Year Ended December 31, 2016	30/17/30	CI
SalvaRx Seeks Investments	30/17/30	CI
SalvaRx Group plc Treats First Patient INT230-6 as Part of A Phase 1/2 International Clinical Study	30/17/30	CI
SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016	13/16/13	CI
Salvarx Group plc Announces Audited Consolidated Earnings Results for the Year Ended 31 December 2015	27/16/27	CI
SalvaRx Seeks Acquisitions	27/16/27	CI
Intensity Therapeutics, Inc. announced that it has received $10 million in funding from Batterson Venture Capital, LLC, Vcapital, Inc., Seed Innovations Limited, SalvaRx Group plc	26/16/26	CI
SalvaRx Limited completed the acquisition of 3Legs Resources plc from BlackRock Investment Management (UK) Limited, British Polar Engines Ltd., Pires Investments PLC, Port Erin Biopharma Investments Limited and other shareholders in a reverse merger transaction.	22/16/22	CI
SalvaRx Limited signed non-binding heads of terms to acquire 3Legs Resources plc from BlackRock Investment Management (UK) Limited, British Polar Engines Ltd., Pires Investments PLC, Port Erin Biopharma Investments Limited and other shareholders in a reverse merger transaction.	04/15/04	CI
SalvaRx Limited announced that it has received £0.43 million in funding from 3Legs Resources plc and other investors.	30/15/30	CI

Chart SalvaRx Group plc

Duration

Period

More charts

Company Profile

SalvaRx Group plc, formerly 3Legs Resources plc, is an investing company. The Company is engaged in drug discovery and development, focused on immune-oncology. The Company's segment is appraisal of investment targets meeting the Company's investment policy. The Company is focused on evaluation and assessment of investment opportunities in line with the investment policy. Its product is IMM60. It expects the study to evaluate approximately three treatment groups: a control arm using the standard of care (an anti-programmed death (PD)-1 therapy), a trial arm using iOX Therapeutics Ltd's drug (IMM60), and a third arm that will test the combination of IMM60 and an anti-PD1 therapy. 3Legs Management Services US LLC is the subsidiary of the Company.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SALVARX GROUP PLC	-.--%	2.16M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs